ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

monalizumab

Also written as “Monalizumab”, “NNC 0141-0000-0100” and “Durvalumab + Monalizumab”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms · Colonic Neoplasms · Leukemia, Lymphocytic, Chronic, B-Cell, led by 2 companies.

Drug pageMonalizumab: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 23, 20209 company-led studies, 3 open or runningLicense: Innate Pharma → AstraZeneca, Oct 2018Next primary completion: Jan 8, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca53 open or runningphase 3since Sep 23, 2020Dec 10, 2018Jan 8, 2027phase 3 · NCT05221840
Innate Pharmaits history only40 open or runningphase 2since Jan 2, 2015May 31, 2011none ahead
  • Named in AstraZeneca’s own pipeline as monalizumab, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: Parexel.

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jun 9, 2015Named monalizumabINNProposed as its International Nonproprietary Name in WHO's List 113 · before, NNC 0141-0000-0100
  2. Oct 23, 2018AstraZeneca licensed it from Innate PharmaLicenseFull rights in cancer, under their 2015 co-development agreement · announced · AstraZeneca
  3. Dec 10, 2018First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03822351 · 189 enrolled · United States, Canada, France and more
  4. Oct 16, 2019Phase 2 study in Colonic NeoplasmsNCT04145193
  5. Sep 23, 2020Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT04590963 · 370 enrolled · United States, Argentina, Australia and more
  6. Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550 · 630 planned · United States, Belgium, Canada and more
  7. Jan 14, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840 · 1,051 enrolled · United States, Australia, Brazil and more
  8. Nov 4, 2026Primary completion moved from 2026-09-30 to 2027-01-08Date moved laterphase 3 · +3 months · NCT05221840

Ahead

  1. Jan 8, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840
  2. May 28, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550

TargetBeta

“A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, monalizumab binds to NKG2A and prev…”NCIt, read by Claude

Other programs on KLRC1

ProgramCompanyFurthest phaseStudies
Anti-NKG2A/Anti-PD-L1 Bispecific Antibody XB628ruleExelixisphase 11

Studies

All 5 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05221840Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more3Active, not recruitingJan 8, 20271,051
NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more2RecruitingMay 28, 2030630
NCT04590963Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more3Active, not recruitingMay 11, 2022370
NCT04145193Colonic Neoplasms2WithdrawnMar 19, 20240
NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more2CompletedJul 18, 2023189

How it is read

Names in the registry

  • “Monalizumab”, 4 entries
  • “NNC 0141-0000-0100”, 3 entries
  • “Durvalumab + Monalizumab”, 1 entry
  • “E3 - mFOLFOX6, durvalumab and monalizumab”, 1 entry
  • “monalizumab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.